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Abstract: The COVID-19 pandemic has important consequences for the mental health of populations.
Patients with cancer, already at risk for poor mental health outcomes, are not expected to be spared
from these consequences, prompting the need for health services to improve responsiveness. This
article presents the research protocol for an implementation study designed to describe the uptake of
a well-studied and recognized system for the treatment of depression and anxiety (Stepped-care)
during the specific context of a Pandemic in an oncological site. The system set-up will be assisted
by a digital platform (MoodUP), where patients undergoing cancer treatment will be screened for
anxiety and depressive symptoms, triaged by severity level and algorithm-matched to recommended
interventions. Patients undergoing cancer treatment at a cancer clinic in Portugal will be invited to
subscribe to the MoodUP platform where they will complete a self-reported questionnaire (Hospital
Anxiety and Depression Scale) to screen their anxiety and depressive symptoms. Data will be
instantly collected, and an algorithm will activate severity-matched intervention suggestions, through
a case manager that will coordinate care. The specific objectives of this study will be to describe
the implementation and acceptability of the care system by patients and staff, the barriers to and
facilitators of implementation, the proportion of patients accessing the system and their pathways
through the various stepped-care interventions, and patient perceptions regarding the feasibility
and appropriateness of the eHealth platform. Moreover, exploratory analyses will be conducted to
describe patterns of anxiety and depression symptoms variation across all patients, as well as within
sociodemographically, clinically and contextually characterized subgroups, to characterize their care
needs and access, as well as to explore for whom the MoodUP care system may be more appropriate.
This study is expected to improve processes for collaborative mental healthcare in oncology and
accelerate the digitalization of services, towards the improvement of mental healthcare access, and
management of high-risk patients, during the COVID-19 pandemic.
Keywords: mental health; COVID-19 pandemic; anxiety; depression; oncology; collaborative healthcare
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1. Introduction
The COVID-19 pandemic is the most severe global health crisis of our recent history
and has important effects on the mental health of populations [1–4]. While these effects
have not yet been fully described and quantified, reports of mental distress are soaring, with
the pandemic and social distancing measures reportedly contributing towards occurrence
of low mood, stress, insomnia, anger, fear, loneliness and a sense of entrapment [2,4–7].
Also, the prevalence of clinically relevant anxiety and depression symptoms are likely
to increase considerably compared to pre-COVID-19 pandemic levels [2,4,8]. Vulnerable
populations for poor mental health include individuals with pre-existing physical and/or
mental health conditions [2,4,5], including patients with cancer. Even before the COVID-19
Pandemic, patients with cancer already had significantly higher rates of depression and
anxiety than the general population [9–12]. A systematic review and meta-analysis has
suggested that depression and anxiety affect more than 20% and 10% of cancer patients, re-
spectively, compared to 5% and 7% of the general population for past-year prevalence [10].
The fact that these patients are also at greater risk of becoming seriously ill or even dying
of COVID-19 [11,12], may lead to disproportionate increases of fear and anxiety in this
population. Consistently, findings from the early stages of the COVID-19 outbreak suggests
a high prevalence of anxiety and depression symptoms in cancer patients [13,14]. Further-
more, it is likely that recurrent outbreaks of COVID-19 will be associated with intermittent
social distancing measures [15,16], with inevitable economic consequences. Learning from
our recent past, economic recession and the associated unemployment, income decline and
debt, will be linked with further negative mental health outcomes and increased health
inequalities [17–19].
Mental disorders are disabling and, if left undetected, even when mild, can progress
in severity and become enduring. Common mental disorders (CMD’s), such as anxiety and
depression, contribute for cumulative disadvantage in patients with cancer, entailing clini-
cally relevant effects on quality of life, functionality, productivity and mortality [9,10,20–25].
Moreover, a recent study has shown that the annual health care use and costs in patients
with cancer are 113% higher when depression is also present, naturally creating a signif-
icant impact on health systems [26]. Despite this evidence, it is consensual that, already
before the pandemic, CMD’s are under-recognized and under-treated among patients with
cancer, with mental health care delivered to fewer than 41% of those in need [9,27]. Possible
barriers include inadequate screening, inability to tackle demand and/or insufficient col-
laborative care [28]. In Portugal, these may reflect conservative rates, since the country has
one of the highest prevalence of CMD’s (23%) in Europe, representing the second largest
cause of disability in the country, while access to mental health care is still below other
European countries [29,30]. Furthermore, access to care is expected to decline due to the
pandemic and its consequences on patients and services. In this context, mental healthcare
service delivery needs to be re-designed to align with the physical distancing restrictions,
while boosting its capacity. Efficient provision of mental health care within routine cancer
care, optimizing health outcomes and quality of life, will be crucial to promote adaptation
to the conditions of the pandemic and to face the crises ahead [9,23].
Collaborative care is a model of mental healthcare delivery with proven effective-
ness in the general population, that may help tackle the mental care treatment gap in
oncology [22,31]. This is a patient-centred mental healthcare model where multidisciplinary
decision-making involves patients, case managers and health professionals, including, but
not limited to, mental health professionals [22,31,32]. Within this model, the stepped-care
strategy is considered optimal. It implies that evidence-based treatment follows successive
levels, implemented and monitored systematically, according to patient needs [32]. The
least resource-intensive treatment (e.g., self-help) is delivered first and care is stepped up
if no significant health benefits are achieved [32]. Despite the growing needs, implemen-
tation of these models has not yet been adequately tested in the context of oncological
care [22]. Moreover, in response to physical distancing, mental healthcare delivery must
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be complemented and expanded via digital health tools, further highlighting the need for
urgent research on their real-world implementation and effectiveness [33].
This sets the rationale for this study, which intends to fill this knowledge and treat-
ment gap by implementing and describing a collaborative stepped-care model to scale-up
mental health care for cancer patients, amid the COVID-19 pandemic. An eHealth triage
system platform (MoodUP) will be used to collect and monitor self-reported psychological
distress (including symptoms of Depression and Anxiety), and to recommend interventions
depending on individual needs, over time. The digital response complies with the social
distancing measures to prevent COVID-19 spreading while ensuring access to existing and
novel services [2]. Moreover, this innovative approach is expected to provide information
and empowerment to better cope with anxiety and depressive symptoms. Thus, here we
specifically aim to describe the implementation and acceptability of the care system by pa-
tients and staff, the barriers to and facilitators of implementation, the proportion of patients
accessing the system and their pathways through the various stepped-care interventions,
and to describe patient perceptions regarding the feasibility and appropriateness of the
eHealth platform. Moreover, exploratory analyses will be conducted to describe patterns
of variation of anxiety and depression symptoms across all patients, as well as within
sociodemographically, clinically and contextually characterized subgroups, to describe
their care needs and access, as well as to explore for whom the MoodUP care system may
be more appropriate. We expect that, in addition to advancing and transferring scientific
and technological knowledge on collaborative mental healthcare in oncology, this work
will rapidly reorient care team to scaled-up and accelerated collaborative mental healthcare
capacity, to improve management of high-risk patients.
2. Materials and Methods
2.1. Study Design and Setting
This observational operationalization study is designed to describe the uptake and
the implementation of a well-studied and recognized stepped-care system, for the treat-
ment of depression and anxiety in patients with cancer, during the specific context of a
pandemic. Amid the COVID-19 pandemic, cancer patients reporting psychological distress
will be referred by the oncology clinical team responsible for their care. Subsequently,
with the assistance of MoodUP, a digital platform developed specifically for this study,
patients will be screened and assessed for symptom severity, leading to the suggestion of
severity-dependent treatment recommendations. The study will have a longitudinal design,
using repeated measures of psychological distress to follow patients sharing a common
experience, namely cancer and exposure to the pandemic context, across a 6 months period
for each patient.
The study will be implemented at the Champalimaud Clinical Centre, where 6500 patients
with cancer are treated, on average, per year. According to prevalence rates for CMD’s in
Portugal (23%) [29] and based on the mentioned numbers, we expect 1500 of the patients
to have CMD symptoms and only a fraction to be referred and accept to participate in the
study. With conservative estimates of a 20% referral rate and 50% acceptance/participation
rate, as well as a drop-out rate of 20%, we expect that 10 patients will complete the study
per month. Participants will be selected based on their willingness to participate, using
convenience sampling, for the total duration of the pandemic and the associated distancing
restrictions with an expected reach number between 120 for 1 year duration and 240 for 2
years duration. The total number of participants will depend on the duration of the pan-
demic and the associated distancing restrictions, with a number between 120 (1 year) and
240 (2 years) expected. The end of the pandemic will be considered when, locally, COVID-19
incidence is low and government containment measures are no longer warranted.
Additionally, we will also invite patients and key stakeholders (health professionals
from oncology and mental health, staff, study managers and administrators) from all
care unit teams participating in the implementation of the MoodUP system, based on
their availability to participate, to provide critical feedback on their testing experience via
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qualitative methods (e.g., online and/or phone individual interviews) to improve its overall
design. Taking into consideration the differences in professional backgrounds among
stakeholders, the number of participants will dependent on the number of interviews to
be carried out until thematic saturation is reached, which is considered when no further
concepts and themes are found and that may occur within 12 interviews [34].
2.2. Study Participants and Eligibility Criteria
Eligible participants will be adult patients (18 years or older) during and/or follow-
ing cancer treatment, reporting feelings of psychological distress at any time during the
COVID-19 pandemic. Participants must be capable of providing informed consent and
have autonomous access to the internet through a mobile phone or computer, or access
the internet via a patient nominated proxy. Patients will be excluded if they do not pro-
vide informed consent, are unable to read and/or understand Portuguese, have cognitive
impairment (such as neurodegenerative disorder, dementia or psychosis) or cerebral metas-
tases, require urgent psychiatric care and/or express suicidal ideation, are under active
treatment for a mental disorder by a psychiatrist or psychologist, or ended treatment less
than two months ago, have a history of psychosis or mania, or if they have an ongoing
substance use disorder.
2.3. Participant-Selection and Consent Process
Patients will be identified by health professionals responsible for their oncology-
related care, who will provide information about the MoodUP system and obtain patient
informed consent. Patients will then be contacted by a MoodUP case manager (e.g., nurse),
that will assist patients on how the system works and who will create personal accounts
to access the online platform. Finally, patients will receive a confirmation link sent to the
email address they provide, and by clicking the link will access a user account confirmation
message granting access to MoodUP.
2.4. Ethics
The protocol was approved by the Champalimaud Foundation Ethics Committee
which provides, in the light of the current legislation, the consent for processing personal
data of patients. The research will comply with the Declaration of Helsinki and the cor-
responding ethical principles, as well as the applicable international, EU and national
directive laws (EU Directive 2004/23/EC), in particular, the General Data Protection Reg-
ulation (EU GDPR) and national data protection laws. Written informed consent will be
required for participation.
2.5. Outcome Assessment
Using participatory action research [35,36] approach, participants (patients) and key
stakeholders (health professionals from oncology and mental health, staff, study managers
and administrators) will be invited to give critical feedback and iteratively evaluate the
MoodUP stepped care system via qualitative methods (e.g., using online and/or phone
individual interviews online and/or phone interviews). The interviews will be used to
explore what patients and key stakeholders think of the MoodUP methods and procedures,
and also about the acceptability of a stepped care system for mental health in the oncological
setting during the pandemic. We will follow an interview protocol similar to other relevant
research in the area of health systems [37] and, as an example, the interviews may include
questions for patients such as “What did you expect from treatment?”, “How well did
the MoodUP solution helped you with the problems you wanted to work?” and “What,
if anything, could have been done differently to improve your experience?”; and for key
stakeholders such as “What are your thoughts about the MoodUP system?”, “How did you
feel taking part of this solution for the patients?” and “What can be done to improve how
the MoodUP system runs?”. The interviews will allow gathering data about the feasibility
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and appropriateness of the MoodUP platform and which procedures are efficient versus
those that are perceived to be problematic and need improvement.
Moreover, anxiety and depression scores will be measured using the Hospital Anxiety
and Depression Scale (HADS), which patients will complete online fortnightly [38–41].
This is a self-report questionnaire with 14 items, divided into subscales for anxiety for
depression symptoms. It has shown good validity in web-based administration, is vali-
dated into Portuguese with good internal consistency (anxiety subscale Cronbach alpha
of 0.76; depression subscale Cronbach alpha of 0.81), and is adequate for the screening of
psychological distress in cancer patients [38–41]. Total HADS scores will be automatically
computed and used to classify distress severity levels as “normal” (0–7), “mild” (8–10),
“moderate” (11–14) and “severe” (15–21) [40,42].
2.6. Covariates
To adjust for possible differences in the experience of psychological distress, socio-
demographic questions will also be asked and will include age, gender, education, em-
ployment status and occupation, perceived household income, marital status, family size
and subjective social status [43]. Clinical variables will also be retrieved retrospectively
from Personal Health Records (e.g., ICD-10 Classification; tumour biology, histological
type, grade, previous/ongoing oncological treatments; Eastern Cooperative Oncology
Group—ECOG—Performance status scale; genetic risk factors; prescribed medication and
other chronic illnesses). Assessment of the proportion of participants who decline, drop-out
and complete treatment will also be collected.
2.7. System of Delivering and Monitoring Mental Health
The MoodUP stepped care system builds on the knowledge of a multidisciplinary
research team with strong know-how on oncology and mental health care, as well as
eHealth technology, with ongoing participation in international projects for mental health
monitoring in patients with cancer. The system will allow for screening and severity
assessment of anxiety and depression symptoms, at baseline and across time, prompting
treatment recommendations based on symptom severity. At baseline, patients will complete
the HADS, that will also be used for follow-up assessments. All patients, irrespective
of baseline distress score, will undergo active symptom monitoring every 2 weeks for
6 months follow-up, and HADS scores will be used to provide graphical feedback on
severity to the patients [44,45]. After baseline assessment, a triage algorithm will alert
the case manager via secure messaging about the HADS scores and symptom range
and will recommend the level of intervention needed. The case manager coordinates
care and makes sure the patient receives information on the recommended personalized
intervention. Intervention is dynamic and varies over time depending on individual-level
scores of distress and associated treatment needs. Nevertheless, patients reaching higher
treatment levels will only step-down treatment levels at the discretion of their providers.
Treatment recommendations will follow 4 intensity steps according to distress levels, as
described in Table 1.
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Table 1. Content of the MoodUP stepped care treatment recommendations.
Step 1. Absent/Nil symptoms—Watchful waiting.
This involves no intervention and is based on the principle of
spontaneous recovery [28,32]. General information for dealing
with psychological distress during the COVID-19 pandemic will
be provided.
Step 2. Mild symptoms—Guided self-help [32]
Guided self-help based on the principles of cognitive
behavioural therapy (CBT) will be provided [46]. Patients will
engage in up to 5 brief weekly interactions (10 to 15 min) with a
trained non-specialist member of the support team, via email or
phone. This intervention will follow a guided self-help support
manual based on international guidelines for remote
Psychological First Aid (PFA) during the COVID-19
outbreak [47]. This is a well-established approach to assist
people in distress, promoting healthy coping and feelings of
safety, calming, and hope [48]. Patients will be asked to describe
their current worries and problems, and to develop and
implement a problem-solving plan. These interactions are not
aimed at developing a patient-therapist relation but are only
meant to give basic psychological support in working through
the self-help method [28,48,49]. Moreover, the guided self-help
support team members cannot prescribe pharmacological
treatment or engage in psychotherapeutic intervention. The
guided self-help manual guidelines allow the team members to
assess whether the case needs a referral to higher levels of
intervention intensity than initially proposed by the
alert system.
Step 3. Moderate symptoms—Consultation
psychiatry/psychology intervention
The case manager will contact the patient for a joint discussion
of the current psychological distress and referral to the oncology
staff. Oncology medical staff will be advised to follow treatment
as usual, as they see fit. Collaborative online/telephone
consultation with a psychiatrist and/or psychologist will be
made available to the oncology staff for discussion of the range
of interventions available.
Step 4. Severe symptoms—Fast-track to liaison
psychiatry/psychology intervention
Immediate referral to liaison psychiatry or psychotherapy will
be performed. Psychiatrist and/or Psychologist decision may
be to refer to step down level of assistance (namely to guided
self-help) or to step up the level of assistance to local or
community/hospital for all patients that did not respond to any
of the previous steps of treatment and require complex and
specialized treatment.
2.8. Technical and Service Description of the MoodUP Platform
The MoodUP platform will be the main tool for integrating recruitment, data collection
and delivery of the scientific results. It was developed and implemented locally, and a
prototype is ready for operationalization (Figure 1).
Security is part of MoodUP platform architecture on all levels: software architecture,
data centre architecture and network architecture. Regarding the data access level, data is
encrypted when inserted at the database. Thus, in the case of a security breach, data would
be unreadable and completely useless to safeguard privacy and data security. To ensure the
security of the system, the architecture was designed so that the inner layer comprises the
Champalimaud Foundation servers that are inaccessible from the outside WWW (internet).
Both servers “Data MoodUP Server” and “Auth MoodUP Server” exist only in the inner
network. Data is located in the “Data MoodUP Server” and all sensitive data is encrypted
in the database, which is not directly accessible from the outside. But even in the remote
possibility of a security breach, data is encrypted and the database is not accessible to
unauthorized users. On the other side, the “Main MoodUP Server” allows access to data
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over “REST over HTTPS”, after request authorization to “Auth Server”, depending on the












Figure 1. MoodUP platform prototype.
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Table 2. MoodUP platform type of users and privileges.
Users Privileges
System Manager
Administration privileges such as creating, altering and deleting
user accounts and altering or deleting data related to the
questionnaires, but cannot access patient responses.
Patient Exclusive access to an individual account and responding only tothe questionnaires assigned by the health professionals.
Case Manager
Access to the administrative data of the patients, created by or
assigned to her/him. Can also create questionnaires or assign
questionnaires to a patient.
The only connection allowed to “Auth and Data MoodUP Servers” is by the main
server’s, hosted by the Champalimaud Foundation. Thus, the whole MoodUP system is
behind the firewall and, the clients have only access to the Main MoodUP Server over
the port 443 HTTPS and port 80 for HTTP, all other ports are closed. Patients and Case
Managers will access the “MoodUP Server” via HTTPS, with ensured security by having
this connection always encrypted. Also, the fragmentation of the system, enforces data
protection for the data server from possible corruption in case of DOS (Distributed denial
of service attack), since the Main Server can only make requests to the Data Server, after
authenticating the user.
2.9. Planned Statistical Analyses
Due to the operational and observational nature of this study, we will essentially
analyse qualitative data and secondarily we will conduct exploratory analysis using the
HADS scale scores over time. Qualitative data on feasibility and appropriateness of the
care system and eHealth platform, once transcribed, will be analysed and coded using an
inductive approach and thematic analysis supported by QSR NVivo 10 software. Prominent
patterns and concepts resulting from the analysis will be identified as themes. Quantitative
and qualitative data may then be merged for improved knowledge around acceptability by
patient categories. For instance, by their sociodemographic characteristics, psychological
distress level, treatment adherence, tumour type and cancer treatment.
Furthermore, we will conduct exploratory analyses, including sociodemographics as
frequency counts and percentages (with ranges where applicable), and continuous data
from HADS scores as means and standard deviations. We will also use descriptive statistics
to explore data about patient pathways using start and end points and whether their treat-
ment was stepped up or down according to the HADS scores. Such analysis will be used
to describe repeated measures of psychological distress, including anxiety and depression
symptoms (compared to baseline HADS anxiety and depression scores), across all patients
and within sociodemographically, clinically and contextually characterized groups, to
understand for whom the system is more appropriate and beneficial. For inference with
longitudinal data we will use linear mixed-effects models which can efficiently use all of
the available data, allow for the characterization of the HADS responses over time while
dealing with complex models for covariance and handling missing data without the need
of imputation. The inclusion of covariates in the models will be informed by the relevant
literature regarding potential confounding effects and univariate analysis. Moreover, we
will also calculate the proportion of enrolled participants who adhered to the MoodUP
system, and the dropout rates. To estimate the loss to follow up bias, we will compare the
characteristics of the participants who drop-out of the study or are lost to follow up, to
minimize the impact of such bias in the analyses. For all analyses power will be calculated
post-hoc, given that the final sample number will be highly dependent on the duration of
the pandemic. Data will be analysed using the SPSS statistical package, assuming type-I
error probability (α) of 0.05.
Int. J. Environ. Res. Public Health 2021, 18, 4629 9 of 11
3. Expected Results/Discussion
This project is expected to develop solutions for scaling-up of mental health care
capacity to patients with cancer, while leveraging scientific and technological knowledge
on the value of an eHealth collaborative mental health stepped care model in oncology.
Furthermore, we expect to deliver a feasible and appropriate digital platform that can be
independently adapted or expanded to different care settings, ensuring know-how transfer
to other healthcare institutions, in order to optimize care at a distance. Notwithstanding, it
is important to anticipate some difficulties that may arise in the implementation. Specif-
ically, there are risks of not having a sufficiently powered sample due to the unknown
referral rate, participation rate and drop-out rate during pandemic. Furthermore, even if
power is sufficient, unforeseen problems in ongoing recruitment processes may lead to a
final sample that may suffer from selection bias and is not representative of the patient
population of interest.
4. Conclusions
This study lays the foundations for a collaborative stepped mental healthcare system
assisted by a digital platform (MoodUP) that will be key for innovative mental health
management among patients with cancer, focused on diagnostic and treatment solutions
to improve their quality of life. This will incorporate improvements in the usual clinical
practice, since the platform can provide real-time feedback to the health professionals
and patients, and may help oncology and mental health teams improve coordination,
liaison and reorientation, to scale-up and accelerate mental healthcare capacity for patient
management amid COVID-19 pandemic, and for future crises.
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